Provided by Tiger Trade Technology Pte. Ltd.

Artelo Biosciences, Inc.

3.26
-0.1100-3.26%
Post-market: 3.19-0.0700-2.15%19:46 EDT
Volume:45.73K
Turnover:152.10K
Market Cap:1.79M
PE:-0.03
High:3.45
Open:3.44
Low:3.19
Close:3.37
52wk High:179.19
52wk Low:3.19
Shares:547.78K
Float Shares:547.42K
Volume Ratio:0.84
T/O Rate:8.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-102.4151
EPS(LYR):-337.9329
ROE:-705.71%
ROA:-127.92%
PB:0.36
PE(LYR):-0.01

Loading ...

Artelo Says Preclinical Osteoarthritis Study Shows Art26.12 Matches Naproxen Pain Relief with Less Gastric Damage

Reuters
·
Jul 16

Artelo Biosciences - to Begin Clinical Multiple Ascending Dose Study of Art26.12 in Q4

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting Art26.12 as a Potential First-in-class New Therapy for Chronic Pain Conditions

THOMSON REUTERS
·
Jul 16

Artelo Biosciences - Art26.12 Shows Efficacy Comparable to Naproxen in Nonclinical Osteoarthritis Study

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Annual Shareholder Meeting

Reuters
·
Jul 14

Artelo Biosciences Reports Positive Preclinical Data for Art27.13 in Paclitaxel-induced Peripheral Neuropathy Model

Reuters
·
Jul 13

Artelo Biosciences - Interim Results Show Improved Body Weight, Lean Mass, Activity, and Safety up to 1300 Μg/day

THOMSON REUTERS
·
Jul 13

Artelo Biosciences - Art27.13 Reduces Neuropathic Pain Behaviors in Paclitaxel-treated Animals

THOMSON REUTERS
·
Jul 13

SK Hynix's Landmark Nasdaq Debut Bets on AI Reshaping Memory Chip Industry's Boom-Bust Cycle

Deep News
·
Jul 11

SK hynix's $26.5 Billion Nasdaq Debut: A Test for Overcoming the 'Korea Discount'

Stock News
·
Jul 10

Artelo Biosciences presents preclinical pain data for ART26.12

TIPRANKS
·
Jul 01

Artelo Biosciences Reports Positive Preclinical Data for Art26.12 in Spinal Cord Injury Neuropathic Pain Model

Reuters
·
Jul 01

Artelo Biosciences Announces New Data Supporting Art26.12 as a Potential First-in-class Therapy for Chronic Pain Associated with Spinal Cord Injury

THOMSON REUTERS
·
Jul 01

Artelo Biosciences Says Phase 1 FABP5 Inhibitor Art26.12 Study Shows Linoleic Acid Signaling Link Across Disease Models

Reuters
·
Jun 30

Bitcoin Mining Firm Ionic Digital Files for Direct Listing on Nasdaq

Stock News
·
Jun 30

Artelo Biosciences Says Phase 1 Study Shows FABP5 Inhibitor Art26.12 is Well Tolerated, with Linear Pharmacokinetics

Reuters
·
Jun 29

Bank of America Issues Warning: Nasdaq Reaches "Bubble Threshold" Driven by Semiconductors

Deep News
·
Jun 25

U.S. Markets Open Mixed as Focus Turns to SpaceX Nasdaq Debut

Deep News
·
Jun 12

Artelo Biosciences reports favorable human metabolite profile for ART26.12 in completed SAD trial

Reuters
·
Jun 10

Artelo Biosciences Launches Flexible At-The-Market Offering

TIPRANKS
·
May 28